Celsion Corporation Announces Strategic Loan Facility
June 28, 2018 08:30 ET | Celsion Corporation
LAWRENCEVILLE, N.J., June 28, 2018 (GLOBE NEWSWIRE) --  Celsion Corporation (NASDAQ: CLSN) (“Celsion” or “the Company”), an oncology drug development company, today announced that on June 27, 2018...
Celsion Corporation to Join Russell Microcap® Index
June 25, 2018 08:00 ET | Celsion Corporation
LAWRENCEVILLE, N.J., June 25, 2018 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced that it will be added to the Russell Microcap® Index...
Celsion Corporation Reports First Quarter 2018 Financial Results and Provides Business Update
May 11, 2018 08:00 ET | Celsion Corporation
Significant Progress in Phase III Liver Cancer and Phase I/II Ovarian Cancer Studies Supported with Solid Fundamentals and a Strong Balance Sheet              Company to Hold Conference...
Celsion Corporation to Present at the RHK Capital 2018 Disruptive Growth and Healthcare Conference
May 08, 2018 08:00 ET | Celsion Corporation
LAWRENCEVILLE, N.J., May 08, 2018 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) announced today that Michael H. Tardugno, Chairman, President and Chief Executive Officer of Celsion, will...
Celsion Corporation to Hold First Quarter 2018 Financial Results Conference Call on Friday, May 11, 2018
May 04, 2018 09:00 ET | Celsion Corporation
LAWRENCEVILLE, N.J., May 04, 2018 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) announced today that the Company will host a conference call to discuss financial results for the quarter...
International Liver Congress™ 2018 Symposium Highlights Celsion’s ThermoDox® in Treatment of Primary Liver Cancer
April 12, 2018 08:00 ET | Celsion Corporation
   LAWRENCEVILLE, N.J., April 12, 2018 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced a presentation and discussion of ThermoDox®,...
Data Monitoring Committee (DMC) Completes Planned Safety and Data Review of Celsion’s Phase III OPTIMA Study of ThermoDox® in Primary Liver Cancer
April 09, 2018 08:30 ET | Celsion Corporation
Blinded Progression-Free Survival (PFS) Rate in the OPTIMA Study is Consistent With the Subgroup Patient Population That Showed Benefit in the HEAT Study ThermoDox®-Highlighted Symposium, “Emerging...
Celsion Corporation Reports Fourth Quarter and Full-Year 2017 Financial Results
March 27, 2018 08:30 ET | Celsion Corporation
Celsion Enters 2018 with Solid Fundamentals, a Strong Balance Sheet and            an Advancing Clinical Pipeline Company to Hold Conference Call on Tuesday, March 27, 2018 at 11:00 a.m. EDT ...
Celsion Corporation to Hold Year-End 2017 Financial Results Conference Call on Tuesday, March 27, 2018
March 20, 2018 08:30 ET | Celsion Corporation
LAWRENCEVILLE, N.J., March 20, 2018 (GLOBE NEWSWIRE) --  Celsion Corporation (NASDAQ: CLSN) announced today that the Company will host a conference call to discuss financial results for the year...
Celsion Corporation to Present at Upcoming Investor Conferences
March 12, 2018 08:00 ET | Celsion Corporation
   LAWRENCEVILLE, N.J., March 12, 2018 (GLOBE NEWSWIRE) --  -- Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced that Michael Tardugno, Chairman,...